Fig. 3.

No expansion or antitumor efficacy of U-CAR-T19 cells in patients with R/R B cell malignancies. a-b Persistence of CAR⁺ CD8⁺ or CD4⁺ cells in vivo after U-CAR-T19 cell infusion. c CAR copies from each patient after U-CAR-T19 cell infusion. A qPCR assay was used to detect the CAR mRNA level in vivo. d Change in CD19⁺ cells after U-CAR-T19 cell infusion in vivo. e MRD of each patient with B-ALL after U-CAR-T19 cell infusion. f NK cell activation in vivo after U-CAR-T19 cell infusion. The CD107a, IFN-γ, TNF-α, and perforin expressions in NK cells were analyzed before and after U-CAR-T19 cell infusion in 14 days. The peak values were compared to the base lines. Statistical significance, two-tailed paired Student’s t test were used, *P < 0.05